Wed, November 2, 2022
Tue, November 1, 2022
Mon, October 31, 2022
Sun, October 30, 2022
Fri, October 28, 2022

Etzer Darout Maintained (YMAB) at Buy with Decreased Target to $12 on, Nov 1st, 2022


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. with-decreased-target-to-12-on-nov-1st-2022.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Etzer Darout of BMO Capital, Maintained "Y-mAbs Therapeutics, Inc." (YMAB) at Buy with Decreased Target from $29 to $12 on, Nov 1st, 2022.

Etzer has made no other calls on YMAB in the last 4 months.



There are 5 other peers that have a rating on YMAB. Out of the 5 peers that are also analyzing YMAB, 2 agree with Etzer's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • David Nierengarten of "Wedbush" Downgraded from Buy to Hold and Held Target at $6 on, Monday, October 31st, 2022
  • Michael Ulz of "Morgan Stanley" Maintained at Hold with Decreased Target to $8 on, Monday, October 31st, 2022


These are the ratings of the 3 analyists that currently disagree with Etzer


  • Robert Burns of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $19 on, Monday, October 31st, 2022
  • Tessa Romero of "JP Morgan" Downgraded from Hold to Sell and Decreased Target to $7 on, Monday, October 31st, 2022
  • William Maughan of "Canaccord Genuity" Maintained at Strong Buy with Decreased Target to $27 on, Monday, October 31st, 2022

Publication Contributing Sources